Rates of Adverse Events in Patients With Ulcerative Colitis Undergoing Colectomy During Treatment With Tofacitinib vs Biologics : A Multicenter Observational Study
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology..
INTRODUCTION: Patients with ulcerative colitis (UC) receiving immunosuppressive drugs are at substantial risk of colectomy. We aimed to assess the risk of postoperative complications of tofacitinib exposure before colectomy in comparison with biologics.
METHODS: A multicenter, retrospective, observational study was conducted in patients with UC who underwent total colectomy for medically refractory disease, exposed to tofacitinib or a biologic before surgery. Primary outcome was the occurrence of any complication within 30 (early) and 90 (late) days after surgery. Secondary outcomes were the occurrence of infections, sepsis, surgical site complications, venous thromboembolic events (VTE), hospital readmissions, and redo surgery within the same timepoints.
RESULTS: Three hundred one patients (64 tofacitinib, 162 anti-tumor necrosis factor-α agents, 54 vedolizumab, and 21 ustekinumab) were included. No significant differences were reported in any outcome, except for a higher rate of early VTE with anti-tumor necrosis factor-α agents ( P = 0.047) and of late VTE with vedolizumab ( P = 0.03). In the multivariate analysis, drug class was not associated with a higher risk of any early and late complications. Urgent colectomy increased the risk of any early (odds ratio [OR] 1.92, 95% confidence interval [CI] 1.06-3.48) complications, early hospital readmission (OR 4.79, 95% CI 1.12-20.58), and early redo surgery (OR 7.49, 95% CI 1.17-47.85). A high steroid dose increased the risk of any early complications (OR 1.96, 95% CI 1.08-3.57), early surgical site complications (OR 2.03, 95% CI 1.01-4.09), and early redo surgery (OR 7.52, 95% CI 1.42-39.82). Laparoscopic surgery decreased the risk of any early complications (OR 0.54, 95% CI 0.29-1.00), early infections (OR 0.39, 95% CI 0.18-0.85), and late hospital readmissions (OR 0.34, 95% CI 0.12-1.00).
DISCUSSION: Preoperative tofacitinib treatment demonstrated a postoperative safety profile comparable with biologics in patients with UC undergoing colectomy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
The American journal of gastroenterology - (2024) vom: 19. März |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 29.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.14309/ajg.0000000000002676 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367946610 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367946610 | ||
| 003 | DE-627 | ||
| 005 | 20240331000917.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240202s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.14309/ajg.0000000000002676 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1357.xml |
| 035 | |a (DE-627)NLM367946610 | ||
| 035 | |a (NLM)38305302 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dragoni, Gabriele |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rates of Adverse Events in Patients With Ulcerative Colitis Undergoing Colectomy During Treatment With Tofacitinib vs Biologics |b A Multicenter Observational Study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 29.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology. | ||
| 520 | |a INTRODUCTION: Patients with ulcerative colitis (UC) receiving immunosuppressive drugs are at substantial risk of colectomy. We aimed to assess the risk of postoperative complications of tofacitinib exposure before colectomy in comparison with biologics | ||
| 520 | |a METHODS: A multicenter, retrospective, observational study was conducted in patients with UC who underwent total colectomy for medically refractory disease, exposed to tofacitinib or a biologic before surgery. Primary outcome was the occurrence of any complication within 30 (early) and 90 (late) days after surgery. Secondary outcomes were the occurrence of infections, sepsis, surgical site complications, venous thromboembolic events (VTE), hospital readmissions, and redo surgery within the same timepoints | ||
| 520 | |a RESULTS: Three hundred one patients (64 tofacitinib, 162 anti-tumor necrosis factor-α agents, 54 vedolizumab, and 21 ustekinumab) were included. No significant differences were reported in any outcome, except for a higher rate of early VTE with anti-tumor necrosis factor-α agents ( P = 0.047) and of late VTE with vedolizumab ( P = 0.03). In the multivariate analysis, drug class was not associated with a higher risk of any early and late complications. Urgent colectomy increased the risk of any early (odds ratio [OR] 1.92, 95% confidence interval [CI] 1.06-3.48) complications, early hospital readmission (OR 4.79, 95% CI 1.12-20.58), and early redo surgery (OR 7.49, 95% CI 1.17-47.85). A high steroid dose increased the risk of any early complications (OR 1.96, 95% CI 1.08-3.57), early surgical site complications (OR 2.03, 95% CI 1.01-4.09), and early redo surgery (OR 7.52, 95% CI 1.42-39.82). Laparoscopic surgery decreased the risk of any early complications (OR 0.54, 95% CI 0.29-1.00), early infections (OR 0.39, 95% CI 0.18-0.85), and late hospital readmissions (OR 0.34, 95% CI 0.12-1.00) | ||
| 520 | |a DISCUSSION: Preoperative tofacitinib treatment demonstrated a postoperative safety profile comparable with biologics in patients with UC undergoing colectomy | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Innocenti, Tommaso |e verfasserin |4 aut | |
| 700 | 1 | |a Amiot, Aurelién |e verfasserin |4 aut | |
| 700 | 1 | |a Castiglione, Fabiana |e verfasserin |4 aut | |
| 700 | 1 | |a Melotti, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Festa, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Savarino, Edoardo Vincenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Truyens, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Argyriou, Konstantinos |e verfasserin |4 aut | |
| 700 | 1 | |a Noviello, Daniele |e verfasserin |4 aut | |
| 700 | 1 | |a Molnar, Tamas |e verfasserin |4 aut | |
| 700 | 1 | |a Bouillon, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Bezzio, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Eder, Piotr |e verfasserin |4 aut | |
| 700 | 1 | |a Fernandes, Samuel |e verfasserin |4 aut | |
| 700 | 1 | |a Kagramanova, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Armuzzi, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Oliveira, Raquel |e verfasserin |4 aut | |
| 700 | 1 | |a Viola, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Ribaldone, Davide Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Drygiannakis, Ioannis |e verfasserin |4 aut | |
| 700 | 1 | |a Viganò, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Calella, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Gravina, Antonietta Gerarda |e verfasserin |4 aut | |
| 700 | 1 | |a Pugliese, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Chaparro, María |e verfasserin |4 aut | |
| 700 | 1 | |a Ellul, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Vieujean, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Milla, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Caprioli, Flavio |e verfasserin |4 aut | |
| 700 | 0 | |a “TOFA-poSTOP” Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Aratari, Annalisa |e investigator |4 oth | |
| 700 | 1 | |a Belli, Francesca |e investigator |4 oth | |
| 700 | 1 | |a Botto, Inês |e investigator |4 oth | |
| 700 | 1 | |a Bretto, Elisabetta |e investigator |4 oth | |
| 700 | 1 | |a Cremer, Anneline |e investigator |4 oth | |
| 700 | 1 | |a Dal Buono, Arianna |e investigator |4 oth | |
| 700 | 1 | |a Giorgi, Domenico A |e investigator |4 oth | |
| 700 | 1 | |a Gisbert, Javier P |e investigator |4 oth | |
| 700 | 1 | |a Kapsoritakis, Andreas |e investigator |4 oth | |
| 700 | 1 | |a Koutroubakis, Ioannis |e investigator |4 oth | |
| 700 | 1 | |a Laffusa, Alice |e investigator |4 oth | |
| 700 | 1 | |a Lobaton, Triana |e investigator |4 oth | |
| 700 | 1 | |a Nardone, Olga Maria |e investigator |4 oth | |
| 700 | 1 | |a Neves, João |e investigator |4 oth | |
| 700 | 1 | |a Oleg, Knyazev |e investigator |4 oth | |
| 700 | 1 | |a Pellegrino, Raffaele |e investigator |4 oth | |
| 700 | 1 | |a Poggioli, Gilberto |e investigator |4 oth | |
| 700 | 1 | |a Rottoli, Matteo |e investigator |4 oth | |
| 700 | 1 | |a Saibeni, Simone |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The American journal of gastroenterology |d 1953 |g (2024) vom: 19. März |w (DE-627)NLM000025445 |x 1572-0241 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:19 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.14309/ajg.0000000000002676 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 19 |c 03 | ||